A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan (PROTECT-ALT)
PROphylactic Efanesoctocog Alfa Therapy Evaluated for Critical Joint Health in Hemophilia A Treatment: The PROTECT-ALT Study
Sponsor: Sanofi
Listed as NCT06684314, this observational or N/A phase trial focuses on Hemophilia A and remains actively recruiting participants. Sponsored by Sanofi, it has been updated 5 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Nov 2025 — Present [monthly]
Recruiting
-
Sep 2025 — Nov 2025 [monthly]
Recruiting
-
Jul 2025 — Sep 2025 [monthly]
Recruiting
-
Feb 2025 — Jul 2025 [monthly]
Recruiting
-
Dec 2024 — Feb 2025 [monthly]
Recruiting
First recorded
Nov 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .